Elements of cancer immunity and the cancer–immune set point
The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But despite the clinical success of antibodies against the immune regulators CTLA4 and PD-L1/PD-1, only a subset of people exhibit durable responses, suggesting that a broader view of cancer immunity is required. Immunity is influenced by a complex set of tumour, host and environmental factors that govern the strength and timing of the anticancer response. Clinical studies are beginning to define these factors as immune profiles that can predict responses to immunotherapy. In the context of the cancer-immunity cycle, such factors combine to represent the inherent immunological status - or 'cancer-immune set point' - of an individual.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This model effectively identifies two main clusters resembling the Immune-Inflamed and Immune-Desert phenotypes42–44”
From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [43]
In the citing paper
“Tumor-infiltrating lymphocytes (TILs) have been proven to be associated with immunotherapy response 245, OS, and PFS 246.”
From Artificial intelligence in pancreatic cancer (2022) · cites this paper as [245]
In the citing paper
“The microbiota influences the cancer-immune set point, which is the threshold beyond which an immune response can be elicited in a given individual.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [11]
In the citing paper
“Recently, it has been demonstrated that the efficacy of the treatment with immune checkpoint inhibitors can be influenced by the composition of the host gut microbiota (176).”
From Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019) · cites this paper as [176]
In the citing paper
“a variety of clinically relevant anticancer interventions including conventional chemotherapeutics (Galluzzi et al., 2020a), radiation therapy (RT) (Rodriguez-Ruiz et al., 2020), and targeted anticancer agents (see main text) have been shown to elicit bona fide ICD and hence jumpstart the cancer-immunity cycle (Chen and Mellman, 2017) in preclinical tumor models.”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chen and Mellman, 2017
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citation
Cited by
Items 701–800 of 1,026
Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety
Ge, Y., Wang, H., Ren, J., Liu, W., Chen, L., Chen, H., Ye, J., Dai, E., Ma, C., Ju, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000710 · Cited by 91
NF-κB in the New Era of Cancer Therapy
Eluard, B., Thiéblemont, C., & Baud, V. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.04.003 · Cited by 91
Chen, Y., Huang, Y., Gao, X., Li, Y., Lin, J., Chen, L., Chang, L., Chen, G., Guan, Y., Pan, L. K., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01620 · Cited by 101
“Immunotherapies targeting immune checkpoints have durable antitumor responses in multiple cancer types, which can contribute to a remarkable improvement in treatment outcomes in a subset of patients with advanced cancer (1).”
BackgroundRadiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges
Qian, J. M., & Schoenfeld, J. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.608772 · Cited by 91
“Tumor mutational burden, a potential surrogate for tumor neoantigens that can be recognized by the immune system, is one such biomarker, leading to the first ever histology-agnostic FDA approval of the PD-1 inhibitor pembrolizumab for mismatch repair deficient tumors of any histology (14, 15), though there is increasi…”
BackgroundTIGIT promotes CD8+T cells exhaustion and predicts poor prognosis of colorectal cancer
Liang, R., Zhu, X., Lan, T., Ding, D., Zheng, Z., Chen, T., Huang, Y. L., Liu, J., Yang, X., Shao, J., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02886-8 · Cited by 96
FOXOs in cancer immunity: Knowns and unknowns
Deng, Y., Wang, F., Hughes, T. L., & Yu, J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.005 · Cited by 90
Correlation between patients' age and cancer immunotherapy efficacy.
Wu, Q., Wang, Q., Tang, X., Xu, R., Zhang, L., Chen, X., Xue, Q., Wang, Z., Shi, R., Wang, F., et al. (2019) · Europe PMC (PubMed Central) · doi:10.1080/2162402x.2019.1568810 · Cited by 106
Zhou, Z., Zhang, B., Zai, W., Kang, L., Yuan, A., Hu, Y., & Wu, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901987116 · Cited by 82
“However, it is disappointing that only a subset of patients positively respond to these therapies, whereas the majority of patients show resistance to PD-L1 blockade (3).”
BackgroundTumor immune response and immunotherapy in gastric cancer
Kwak, Y., Seo, A. N., Lee, H. E., & Lee, H. S. (2019) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2019.10.08 · Cited by 93
“The role of helper T cells in tumor immunity has yet to be fully elucidated, but their main role is to aid humoral immunity via B cell antibody secretion and to enhance the function of cytotoxic T cells [13].”
BackgroundTumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy?
He, Y., Liu, T., Dai, S., Xu, Z., Wang, L., & Luo, F. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.739161 · Cited by 93
“As mentioned above, each step of the Cancer-Immunity Cycle requires the coordination of numerous factors, both stimulatory and inhibitory in nature (Chen and Mellman, 2017).”
BackgroundPérez-Baños, A., Gleisner, M. A., Flores, I., Pereda, C., Navarrete, M., Araya, J. P., Navarro, G., Quezada-Monrás, C., Tittarelli, A., & Salazar‐Onfray, F. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02327-6 · Cited by 101
“Indeed, patients with significant lymphocyte accumulation within the TME are more likely to respond [139].”
BackgroundImmune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC)
Yoneda, K., Imanishi, N., Ichiki, Y., & Tanaka, F. (2018) · Journal of UOEH · doi:10.7888/juoeh.40.173 · Cited by 84
The multifaceted effects of metformin on tumor microenvironment
Kurelac, I., Umesh Ganesh, N., Iorio, M., Porcelli, A. M., & Gasparre, G. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.05.010 · Cited by 81
“On the other hand, tumors often harbor high numbers of protumorigenic regulatory T-cells (Treg), which support tumor growth by promoting wound-healing-like signals [50].”
BackgroundSalehi‐Rad, R., Li, R., Paul, M. K., Dubinett, S. M., & Liu, B. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.10.003 · Cited by 94
Pan, Q., Wang, L., Chai, S., Zhang, H., & Li, B. (2020) · Journal of Cancer · doi:10.7150/jca.37285 · Cited by 95
“Among these non-cancer cells, the tumor infiltrating immune cells (TIICs) exert a central role in pro- and anti-tumorigenic processes; moreover, they have been found closely correlated with the clinical outcome and response to immunotherapy [6].”
Pinto, S., Pahl, J. H. W., Schottelius, A. J. G., Carter, P. J., & Koch, J. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.09.007 · Cited by 88
Segal, N. H., Melero, I., Moreno, V., Steeghs, N., Marabelle, A., Rohrberg, K., Rodriguez-Ruiz, M. E., Eder, J. P., Eng, C., Manji, G. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48479-8 · Cited by 80
Conroy, J. M., Pabla, S., Glenn, S. T., Burgher, B., Nesline, M., Papanicolau‐Sengos, A., Andreas, J., Giamo, V., Lenzo, F. L., Hyland, F. C. L., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.10.001 · Cited by 84
Integrating molecular nuclear imaging in clinical research to improve anticancer therapy
de Vries, E. G. E., de Ruijter, L. K., Hooge, M. N. L., Dierckx, R. A. J. O., Elias, S. G., & Oosting, S. F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0123-y · Cited by 86
Jensen, C., Madsen, D. H., Hansen, M., Schmidt, H., Svane, I. M., Karsdal, M. A., & Willumsen, N. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0474-z · Cited by 79
Wu, X., Qu, D., Weygant, N., Peng, J., & Houchen, C. W. (2020) · Cancers · doi:10.3390/cancers12020274 · Cited by 83
Ohmura, H., Yamaguchi, T., Hanamura, F., Ito, M., Makiyama, A., Uchino, K., Shimokawa, H., Tamura, S., Esaki, T., Mitsugi, K., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0810-1 · Cited by 81
Zeng, X., Liu, G., Pan, Y., & Li, Y. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15097 · Cited by 84
A perspective on HPK1 as a novel immuno-oncology drug target
Sawasdikosol, S., & Burakoff, S. J. (2020) · eLife · doi:10.7554/elife.55122 · Cited by 84
“The lack of broad therapeutic efficacy highlights the need to identify biomarkers capable of predicting either which type of cancer or which biomarker sub-stratums would respond best to the therapy (Chen and Mellman, 2017; Havel et al., 2019).”
BackgroundNext-generation cytokines for cancer immunotherapy
Xue, D., Hsu, E. J., Fu, Y., & Peng, H. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab014 · Cited by 96
Ju, F., Luo, Y., Lin, C., Jia, X., Xu, Z., Tian, R., Lin, Y., Zhao, M., Chang, Y., Huang, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004762 · Cited by 91
Wang, J., Xie, T., Wang, B., William, W. N., Heymach, J. V., El‐Naggar, A. K., Myers, J. N., & Caulín, C. (2017) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-17-0108 · Cited by 85
“To overcome the antineoplastic effects of the immune system, tumor cells may transmit immunosuppressive signals to the tumor microenvironment that enable cancer progression (17, 18).”
BackgroundEmerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Li, X., Song, W., Shao, C., Shi, Y., & Han, W. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0086-z · Cited by 82
“INTRODUCTION Immunity in cancer patients is influenced by a complex network of tumor, host, and environmental factors that govern the threshold, strength, and timing of antitumor immunity.(1) There is clear evidence that the immune system can mount cytotoxic immune responses that can eradicate tumor cells as “foreign”…”
BackgroundKasikova, L., Hensler, M., Truxova, I., Skapa, P., Laco, J., Belicova, L., Praznovec, I., Vosahlikova, S., Halaska, M. J., Brtnicky, T., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0781-z · Cited by 79
Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?
De Bruyn, P., Van Gestel, D., Ost, P., Kruse, V., Brochez, L., Van Vlierberghe, H., Devresse, A., del Marmol, V., Le Moine, A., & Aspeslagh, S. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000505 · Cited by 79
Argentiero, A., Summa, S. D., Fonte, R., Iacobazzi, R. M., Porcelli, L., Vià, M. D., Brunetti, O., Azzariti, A., Silvestris, N., & Solimando, A. G. (2019) · Cancers · doi:10.3390/cancers11070942 · Cited by 80
CD38 and Regulation of the Immune Response Cells in Cancer
Dwivedi, S., Rendon‐Huerta, E. P., Ortiz-Navarrete, V. F., & Montaño, L. F. (2021) · Journal of Oncology · doi:10.1155/2021/6630295 · Cited by 100
“However, CD38 +TILs provide antitumor responses through secretion of cytotoxic compounds and inflammatory cytokines [61, 62].”
BackgroundRadiation-Induced Immunity and Toxicities: The Versatility of the cGAS-STING Pathway
Constanzo, J., Faget, J., Ursino, C., Badie, C., & Pouget, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680503 · Cited by 91
“For instance, CD4 and CD8 T cells produce IFN-g, contributing to the formation of an inflammatory environment that favors the anti-tumor immunity (72).”
BackgroundAndersen, L. B., Nørgaard, M., Rasmussen, M., Fredsøe, J., Borre, M., Ulhøi, B. P., & Sørensen, K. D. (2021) · The Journal of Pathology · doi:10.1002/path.5757 · Cited by 89
Immune Tumor Microenvironment in Ovarian Cancer Ascites
Almeida-Nunes, D. L., Mendes‐Frias, A., Silvestre, R., Dinis‐Oliveira, R. J., & Ricardo, S. A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810692 · Cited by 95
Valenza, C., Salimbeni, B. T., Santoro, C., Trapani, D., Antonarelli, G., & Curigliano, G. (2023) · Cancers · doi:10.3390/cancers15030767 · Cited by 91
“In fact, according to a fascinating but non-reproducible classification, a tumor can be considered "hot" or "inflamed" if characterized by an abundant immune-infiltrate, "intermediate" or "immune-excluded" if lymphocytes are present in the peritumoral stroma only, or "cold" or "immune-desert" if it is largely devoid o…”
Shen, M., Wang, Y., Bing, T., Tang, Y., Liu, X., & Yu, Y. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202307013 · Cited by 78
Davis, M. M., & Brodin, P. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053206 · Cited by 77
“Other sources of candidate antigens may come from mass spectrometry analysis of peptides eluting from MHC proteins, and this approach has been used to identify tumor antigens (24), but in many cases the possibilities are much more open ended.”
BackgroundPresent and future of cancer immunotherapy: A tumor microenvironmental perspective (Review)
Yu, Y., & Cui, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9219 · Cited by 110
“Therefore, due to the heterogeneity of immune cells in the tumor immune microenvironment, Chen et al (45) divided it into three phenotypes according to the distribution of immune cells, as follows: i) Immune‑inflamed phenotype, where intratumor infiltration of CD4 + and CD8 + T cells, and…”
Budczies, J., Seidel, A., Christopoulos, P., Endris, V., Kloor, M., Győrffy, B., Seliger, B., Schirmacher, P., Stenzinger, A., & Denkert, C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1526613 · Cited by 78
“In general, high PD-L1 expression levels either in tumor cells or immune cells help to identify subsets of patients that benefit from PD-1 or PD-L1 inhibitors,(9,10) but PD-L1 testing is rather coarsely granular and does not account for the complexity of cancerimmune cell interactions.(11)While detection of PD-L1 expr…”
BackgroundKhan, Z., Hammer, C., Guardino, E., Chandler, G. S., & Albert, M. L. (2019) · Genome Medicine · doi:10.1186/s13073-019-0652-8 · Cited by 85
Solman, I. G., Blum, L. K., Hoh, H. Y., Kipps, T. J., Burger, J. A., Barrientos, J. C., O'Brien, S. M., Mulligan, S. P., Kay, N. E., Hillmen, P., et al. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106432 · Cited by 83
Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides
Vitale, I., Yamazaki, T., Wennerberg, E., Sveinbjørnsson, B., Rekdal, Ø., Demaria, S., & Galluzzi, L. (2021) · Trends in cancer · doi:10.1016/j.trecan.2020.12.012 · Cited by 84
Zhou, B., Gao, Y., Zhang, P., & Chu, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693609 · Cited by 91
Rationally designed short cationic α-helical peptides with selective anticancer activity
Hadianamrei, R., Tomeh, M. A., Brown, S., Wang, J., & Zhao, X. (2021) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2021.08.200 · Cited by 89
Understanding Drug Sensitivity and Tackling Resistance in Cancer
Tyner, J. W., Haderk, F., Kumaraswamy, A., Baughn, L. B., Van Ness, B., Liu, S., Marathe, H., Alumkal, J. J., Bivona, T. G., Chan, K. S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3695 · Cited by 78
Lv, T., Xiong, X., Yan, W., Liu, M., Xu, H., & He, Q. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004763 · Cited by 86
Gut microbiome in gastrointestinal cancer: a friend or foe?
Liu, Y., Baba, Y., Ishimoto, T., Gu, X. J., Zhang, J., Nomoto, D., Okadome, K., Baba, H., & Qiu, P. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69331 · Cited by 85
“One case report showed that two cancer patients had significantly abrogated colitis caused by ICIs after FMT. Preliminary data analysis has shown that the application of healthy gut microbes can eliminate ICIassociated colitis, restore the gut microenvironment and increase the density of Tregs in the colonic mucosa.”
BackgroundInfluentialExercise and immunometabolic regulation in cancer
Koelwyn, G. J., Zhuang, X., Tammela, T., Schietinger, A., & Jones, L. W. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00277-4 · Cited by 91
Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
Kim, C.-G., Sang, Y. B., Lee, J. H., & Chon, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158035 · Cited by 83
Liu, J., Chen, C., Wang, Y., Qian, C., Wei, J., Xing, Y., & Bai, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.746647 · Cited by 96
“This immunological profile corresponds to a tumor immune-inflamed phenotype (47), and tumor patients with this profile are the most responsive to immunotherapy, and m1A cluster-B patients do show a matched survival advantage (Figure 2B).”
BackgroundImmune organoids: from tumor modeling to precision oncology
Dao, V. A., Yuki, K., Lo, Y., Nakano, M., & Kuo, C. J. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.06.001 · Cited by 84
Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects
Gupta, M., Wahi, A., Sharma, P., Nagpal, R., Raina, N., Kaurav, M., Bhattacharya, J., Oliveira, S. M. R., Dolma, K. G., Paul, A. K., et al. (2022) · Vaccines · doi:10.3390/vaccines10122011 · Cited by 90
Trial Watch: Adoptively transferred cells for anticancer immunotherapy
Fournier, C., Martin, F., Zitvogel, L., Kroemer, G., Galluzzi, L., & Apétoh, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1363139 · Cited by 82
Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology
Finotello, F., & Eduati, F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00430 · Cited by 81
“But immune cells can also induce immunosuppression and support tumor growth, as in the case of regulatory T (Treg) cells, M2 macrophages, and myeloid-derived suppressor cells (MDSCs) (6, 7, 10, 11).”
BackgroundEvolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment
Luo, Y., Yang, J., Yu, J., Liu, X., Yu, C., Hu, J., Shi, H., & Ma, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00048 · Cited by 81
“, interleukin (IL)-12, IL-1β, and type I and type II interferons (IFNs)] in the tumor parenchyma (5, 6).”
BackgroundMethodNews on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 79
Hispidulin: A promising flavonoid with diverse anti-cancer properties
Liu, K., Zhao, F., Yan, J., Xia, Z., Jiang, D., & Ma, P. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118395 · Cited by 83
The Effects of Localized Heat on the Hallmarks of Cancer
Hannon, G., Tansi, F. L., Hilger, I., & Prina‐Mello, A. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000267 · Cited by 83
Applying nanotechnology to boost cancer immunotherapy by promoting immunogenic cell death
Fu, L., Ma, X., Liu, Y., Xu, Z., & Sun, Z. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.10.074 · Cited by 78
Sun, L., Li, Y., Yu, Y., Wang, P., Zhu, S., Wu, K., Liu, Y., Wang, R., Min, L., & Chang, C. (2022) · Research · doi:10.34133/2022/9860679 · Cited by 83
Emerging Trends in Immunotherapy for Cancer
Mishra, A. K., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022) · Diseases · doi:10.3390/diseases10030060 · Cited by 88
“The checkpoint proteins are expressed on the surface of immune cells and help them distinguish between self and non-self by interacting with their cognate ligands [5,13,14,18].”
BackgroundMachine learning reveals diverse cell death patterns in lung adenocarcinoma prognosis and therapy
Wang, S., Wang, R., Hu, D., Zhang, C.-X., Cao, P., & Huang, J. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00538-5 · Cited by 94
Immune checkpoint inhibitors in colorectal cancer: limitation and challenges
Yan, S., Wang, W., Feng, Z., Xue, J., Liang, W., Wu, X., Tan, Z., Zhang, X., Zhang, S., Li, X., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1403533 · Cited by 93
“Bioinformatics analysis studies have shown that transcriptional pro fi les enriched in IFN-g -responsive genes are positively associated with prognosis and response to anti-tumor immunotherapy (61).”
BackgroundImmune oncology, immune responsiveness and the theory of everything
Turan, T., Kannan, D., Patel, M., Matthew Barnes, J., Tanlimco, S. G., Lu, R., Halliwill, K., Kongpachith, S., Kline, D. E., Hendrickx, W., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0355-5 · Cited by 75
“microenvironment: an immune-active, an opposite immune-deserted and an intermediate immune-excluded [4].”
BackgroundHaikala, H. M., Anttila, J. M., Marques, E., Raatikainen, T., Ilander, M., Hakanen, H., Ala-Hongisto, H., Savelius, M., Balboa, D., Von Eyss, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08541-2 · Cited by 75
A user's perspective on GeoMxTM digital spatial profiling
Van, T. M., & Blank, C. U. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.05.001 · Cited by 73
Nanotheranostics Targeting the Tumor Microenvironment
Roma‐Rodrigues, C., Pombo, I., Raposo, L. R., Pedrosa, P., Fernandes, A. R., & Baptista, P. V. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00197 · Cited by 85
“, cytokines and chemokines) are secreted, resulting in the enrollment of cells from both innate and adaptive immune systems (Chen and Mellman, 2017; Clark, 2018).”
BackgroundSystematic construction and validation of an immune prognostic model for lung adenocarcinoma
Luo, C., Lei, M., Zhang, Y., Zhang, Q., Li, L., Lian, J., Liu, S., Wang, L., Pi, G., & Zhang, Y. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14719 · Cited by 104
Kitsou, M., Ayiomamitis, G. D., & Zaravinos, A. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5062 · Cited by 86
“Primarily, TILs appear in the human body to indicate the existence of the host, thus reflecting the dynamic process of cancer immunization (14,15).”
BackgroundSilva, P. D., Saad, M. A., Thomsen, H., Bano, S., Ashraf, S., & Hasan, T. G. (2020) · Journal of Porphyrins and Phthalocyanines · doi:10.1142/s1088424620300098 · Cited by 83
Yang, Q., Chen, M., Gu, J., Niu, K., Zhao, X., Zheng, L., Xu, Z., Yu, Y., Li, F., Meng, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.665133 · Cited by 84
“As effective as ICIs treatment can be, only 10–40% of patients obtain dramatic responses (3), and the five-year overall survival (OS) rate of ICIs treatment ranges from 15.”
BackgroundBeziaud, L., Young, C. M., Alonso, A. M., Norkin, M., Minafra, A. R., & Huelsken, J. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.05.007 · Cited by 85
Tissue-resident immune cells: from defining characteristics to roles in diseases
Li, J., Chu, X., Li, C., & He, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02050-5 · Cited by 102
Andersen, R. S., Borch, T. H., Draghi, A., Gokuldass, A., Rana, M. A. H., Pedersen, M., Nielsen, M., Kongsted, P., Kjeldsen, J. W., Westergaard, M. C. W., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy139 · Cited by 79
Chae, Y. K., Anker, J. F., Oh, M. S., Bais, P., Namburi, S., Agte, S., Giles, F. J., & Chuang, J. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-39594-4 · Cited by 79
Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images
Wang, C., Ma, J., Shao, J., Zhang, S., Liu, Z., Yu, Y., & Li, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.813072 · Cited by 86
“In addition, although the treatment strategy for NSCLC has rapidly evolved with the emergence of targeted therapy and immunotherapy, persistent drug responses remain limited to a subset of patients, such as the response rates of ICIs ranged from 14% to 20% in unselected patients (20, 21).”
BackgroundYu, K.-X., Yuan, W.-J., Wang, H.-Z., & Li, Y. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03675-9 · Cited by 96
“Tumors lacking cytotoxic T lymphocyte infiltration are termed immune-excluded tumor, which are particularly resistant to various types of treatments [66].”
BackgroundCorrelates of immune and clinical activity of novel cancer vaccines
van der Burg, S. H. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.04.001 · Cited by 77
“Such noninflamed tumors have a low capacity to attract T cells, and therefore are not likely to respond to vaccination or other individual immunotherapies [23].”
BackgroundSecond-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review
Tannir, N. M., Pal, S. K., & Atkins, M. B. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0534 · Cited by 79
“Bleeding disorders in dialysis patients may preclude the use of VEGFR TKIs, although limited data are available for dialysis patients [56, 57].”
BackgroundInfluentialConstruction of immune‐related risk signature for renal papillary cell carcinoma
Wang, Z.-Y., Song, Q., Yang, Z., Chen, J., Shang, J., & Ju, W. (2018) · Cancer Medicine · doi:10.1002/cam4.1905 · Cited by 53
The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier
Pai, S. I., Cesano, A., & Marincola, F. M. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_6 · Cited by 82
“A prevailing phenomenon observed in immune resistant cancers is an absent dialog between the cancer and immune cells [2].”
BackgroundBiomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 79
Risk-associated alterations in marrow T cells in pediatric leukemia
Bailur, J. K., McCachren, S. S., Pendleton, K. E., Vasquez, J. C., Lim, H. S., Duffy, A. M., Doxie, D. B., Kaushal, A., Foster, C., DeRyckere, D., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140179 · Cited by 70
“It is increasingly appreciated, mostly from studies in adult cancer, that properties of the immune microenvironment are a critical determinant of outcome following immune therapies (8, 9).”
InfluentialCell and tissue engineering in lymph nodes for cancer immunotherapy
Najibi, A. J., & Mooney, D. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.023 · Cited by 80
“Because LNs are well recognized for their roles in anticancer immunity [6,39,42], we will devote the rest of this section to discussing the more uncertain relationship between TLS and cancer.”
BackgroundJie, X., Chen, Y., Zhao, Y., Yang, X., Xu, Y., Wang, J., Meng, R., Zhang, S., Dong, X., Zhang, T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003716 · Cited by 84
Gallic acid induces T-helper-1-like T reg cells and strengthens immune checkpoint blockade efficacy
Deng, B., Yang, B., Chen, J., Wang, S., Zhang, W., Guo, Y., Han, Y., Li, H., Dang, Y., Yuan, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004037 · Cited by 88
Küçükköse, E., Heesters, B. A., Villaudy, J., Verheem, A., Cercel, M. G., van Hal, S., Boj, S. F., Rinkes, I. H. M. B., Punt, C. J. A., Roodhart, J. M. L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005345 · Cited by 78
“E), Anti-human IgG immunohistochemistry showed that both therapeutic antibodies were present within and throughout the peritoneal metastases, suggesting that the lack of treatment efficacy was not due to poor drug distribution (online supplemental figure S6).”
Kim, D. J., Dunleavey, J. M., Xiao, L., Ollila, D. W., Troester, M. A., Otey, C. A., Li, W., Barker, T. H., & Dudley, A. C. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0072-3 · Cited by 77
“In addition to underlying genetic factors including mutational load, variability in CAF recruitment or differential activation of CAFs from patient-to-patient may impair the success of immune checkpoint inhibitors.(6) Compared to their normal counterparts, CAFs are typically more contractile, they over-express pro-ang…”
BackgroundNucleic Acid-Based Approaches for Tumor Therapy
Hager, S., Fittler, F. J., Wagner, E., & Bros, M. (2020) · Cells · doi:10.3390/cells9092061 · Cited by 81
Helmlinger, G., Sokolov, V., Peskov, K., Hallow, K. M., Kosinsky, Y., Voronova, V., Chu, L., Yakovleva, T., Azarov, I., Kaschek, D., et al. (2019) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12426 · Cited by 72
“Despite the relative wealth of such data, quantitative modeling remains challenging given it needs to include a mechanistic description of the cancer immunity cycle, which is characterized by highly dynamic and interactive biological processes, with a vast variety of factors influencing them.(80,81)”
BackgroundCharacterization of human cancer xenografts in humanized mice
Rios‐Doria, J., Stevens, C., Maddage, C. J., Lasky, K., & Koblish, H. K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000416 · Cited by 75
The Immune Consequences of Lactate in the Tumor Microenvironment
Harmon, C., O’Farrelly, C., & Robinson, M. W. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43093-1_7 · Cited by 78
“A dynamic network of cytokines, growth factors, and extracellular matrix-degrading enzymes develops, which collectively result in significant alterations in the tissue architecture, dysregulated proliferation and immune dysfunction (Hanahan and Weinberg, 2011; Chen and Mellman, 2017).”
BackgroundThe future of cancer immunotherapy: DNA vaccines leading the way
Pandya, A., Shah, Y., Kothari, N., Postwala, H., Shah, A., Parekh, P., & Chorawala, M. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02060-3 · Cited by 71
Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer
Liu, D., Che, X., Wang, X., Ma, C., & Wu, G. (2023) · Pharmaceuticals · doi:10.3390/ph16101384 · Cited by 94
Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
Zhang, C., Fan, Y., Che, X., Zhang, M., Li, Z., Li, C., Wang, S., Wen, T., Hou, K., Shao, X., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00760 · Cited by 69
Cai, Z., Chen, J., Yu, Z.-Z., Li, H., Liu, Z., Deng, D., Liu, J., Chen, C., Zhang, C., Ou, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202207155 · Cited by 86
Nanovaccine-based strategies for lymph node targeted delivery and imaging in tumor immunotherapy
He, A., Li, X., Dai, Z., Li, Q., Zhang, Y., Ding, M., Wen, Z., Mou, Y., & Dong, H. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01989-x · Cited by 87
“Meanwhile, the tumor microenvironment may suppress the above effector cells and thus disrupt the antitumor immune response [40, 41].”
BackgroundChimote, A. A., Balajthy, A., Arnold, M. J., Newton, H. S., Hajdú, P., Qualtieri, J. N., Wise-Draper, T. M., & Conforti, L. (2018) · Science Signaling · doi:10.1126/scisignal.aaq1616 · Cited by 75
“Thus, understanding how the TME limits T cell infiltration is necessary for improving immune surveillance in cancer and developing effective immunotherapies.”
BackgroundInfluential
Metadata
- Authors
- Chen, D. S., & Mellman, I.
- Affiliations
- Genentech (US)
- Corresponding author
- Mellman, Ira
- Venue
- Nature
- Published
- 2017-01
- Volume
- 541
- Issue
- 7637
- Pages
- 321-330
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2578528809
- Cited by
- 5,352
- References
- 121
- Citations by year
- 2026: 524 · 2025: 527 · 2024: 626 · 2023: 708 · 2022: 848 · 2021: 681 · 2020: 582 · 2019: 386 · 2018: 335 · 2017: 131
- FWCI
- 41.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- antitumor immunity, cancer-immunity cycle, immunotherapy response, CTLA-4, PD-1/PD-L1, immune checkpoint inhibitors, tumor immune microenvironment, immunological profile, predictive biomarkers, durable response
- MeSH terms
- Animals, Humans, Immunologic Memory, Immunotherapy, Inflammation, Neoplasms, T-Lymphocytes, Genome, Human, Tumor Escape, Epigenesis, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.